#world pharma market size | Explore Tumblr posts and blogs

mariacallous · 2 years ago

Text

A strange thing happened in the eurozone economy at the end of last year. Despite widespread forecasts that the common currency area would plunge into recession and register negative growth in the last quarter of 2022, it managed to eke out a small gain of 0.1 percent. What is remarkable is not that Europe beat expectations, but that it was one small country—Ireland—whose surging economy single-handedly prevented the eurozone from slipping into the red.

Almost unbelievably, little Ireland, with a population of only 5 million, now has the economic scale to shift the growth statistics of the entire eurozone and its 343 million inhabitants. In 2022, Irish GDP growth of 12.2 percent compared to 3.5 percent in the eurozone as a whole. In absolute numbers, only Germany, France, and Italy contributed more than Ireland to eurozone GDP growth in 2021 and 2022. Ireland’s economic boom has enabled the country’s government to post a budget surplus of 1.6 percent of GDP, even as eurozone countries struggled with an average deficit of more than 3 percent.

Honestly, who wouldn’t want this luck of the Irish?

Look closely, however, and Ireland’s so-called economic miracle looks more than a little odd. The country’s growth is simultaneously both real and artificial. Much of it is driven by a handful of U.S. multinationals, which continue to route global sales and profits through their Irish operations to take advantage of Dublin’s lower business taxes. Although difficult and complex to calculate, Apple’s shifting of intellectual property assets to Ireland is estimated to have contributed half of Ireland’s miraculous 26 percent GDP growth in 2016. That bizarre fact inspired New York Times columnist Paul Krugman to ridicule Ireland’s “leprechaun economics”—and the Irish statistics office to move away from using GDP as a measure of economic growth.

Yet the surge of U.S. investment in Ireland is also real. In particular, Ireland’s role as a pharmaceuticals manufacturing hub dramatically increased during the COVID-19 pandemic. Nine out of the world’s top 10 drug companies have significant production facilities in Ireland. The U.S. State Department thinks the corporate build-out in Ireland will continue, given Ireland’s status as the only remaining English-speaking European Union country following Britain’s departure. That makes it easy for international companies to operate and enjoy barrier-free access to the EU’s single market.

It’s hard to exaggerate Ireland’s dependence on U.S. tech and pharma companies for investment and taxes. Corporate tax receipts are now the second-largest source of tax revenue (after income tax) for the Irish state: 27 percent of all tax income in 2022. The average was just 9 percent in the 38 member countries of the Organisation for Economic Co-operation and Development (OECD) in 2020, the last year for which data is available. This, in turn, is fueling an unprecedented torrent of tax income for the Irish government. Corporate tax revenues were up nearly 50 percent in 2022 alone.

Just 10 multinationals—all of them U.S.-based tech and pharmaceutical companies—now pay nearly 60 percent of Ireland’s corporate tax. Directly and indirectly, U.S. multinationals employ more than 375,000 people in Ireland, approximately 15 percent of the country’s labor force. Driven by investment from the United States, foreign multinationals now account for 53 percent of all payroll taxes paid by corporate employers.

Driven by the windfall in corporate tax receipts, the Irish government’s budget surplus is expected to swell further, to 10 billion euros in 2023 and 16 billion euros in 2024. Relative to the size of the economy, this would be equivalent to a U.S. budget surplus of more than 1 trillion dollars in 2024.

The problem for Ireland is that this singular dependence exposes the country to growing risks. Take the tech sector: As multinationals like Google, Microsoft, Meta, and Amazon see their profits shrink and slash jobs worldwide, it will not only hurt the Irish economy, but deprive Dublin of tax income as well.

What’s more, the threat to Ireland’s stability from its overdependence on U.S. companies is about to be multiplied. In 2021, nearly 140 tax jurisdictions, including Ireland, agreed to a major reform of how multinationals companies will be taxed in the future. Pillar 2 of these reforms—a minimum corporate tax rate of 15 percent for large companies—is already coming into effect. In 2024, Ireland’s corporate tax rate is due to increase to 15 percent from its current level of 12.5 percent, reducing its attractiveness as a tax haven compared to other countries. The United States also approved the minimum tax plan in August 2022, despite significant private sector and political opposition.

However, it is Pillar 1 of the OECD’s reforms that will dramatically erode Ireland’s future income from corporate taxes. This reform will reallocate a share of company profits to where sales (or users) are actually located. Previously, tax liability was calculated on where the company or its subsidiary was legally based, no matter how many profits it rerouted from other parts of the world for tax-avoiding purposes. For Ireland, the consequences are obvious: U.S. multinationals operating in the EU will be forced to divide some of their sales by member state, thus significantly reducing the amount of sales and profits that can be “booked” through Ireland. This reform is due to come into force in 2024. The end of Ireland’s windfall is therefore only a matter of time.

The Irish Department of Finance estimated in January that around half of Ireland’s corporate tax receipts—$10 billion—are “transitionary” and will be lost as the new tax rules are implemented. That translates to more than 10 percent of total government spending in 2022—more than the entire Irish education budget. This is putting the Irish government on the precipice of another financial disaster, little more than a decade after it had to be bailed out of impending bankruptcy by the European Commission, European Central Bank, and the International Monetary Fund. That disaster left Ireland with one of the highest per capita public debt levels in the world.

Regardless of the impending financial train wreck, however, Dublin is unlikely to wake up from its American dream anytime soon. Diversifying its economy and revenue sources away from U.S. multinationals would require Ireland to shift its economic and geopolitical orientation, downgrade (in Dublin’s eyes) its deep relationship with the United States, and seek greater integration into the EU economy and its myriad rules.

That’s because Ireland’s dependence on U.S. multinationals is just another expression of the country’s affinity with the United States—the “shared heritage” referenced by U.S. presidents from John F. Kennedy to Ronald Reagan to Joe Biden. These ties to the United States long precede Dublin’s embrace of European integration and make it unlikely that Ireland will ever have the same intensity of economic, cultural, and other ties to France, Germany, or the rest of the EU.

The approaching economic and fiscal train wreck resulting from the new tax rules requires a fundamental change of mindset from Irish policymakers. Squaring the circle—holding on to its deep U.S. ties while integrating more closely with the EU to diversify its economy—means Dublin must give a little (and lose a little) to both sides. Yet Ireland’s ability to navigate this conundrum is doubtful. Even though the coming changes have been plain for all to see, Dublin’s current Trade and Investment Strategy does not contain any concrete policies to mitigate the overdependence on U.S. investment flows. Although the document acknowledges that EU market opportunities are underutilized, it again recognizes the importance “markets such as the UK and the US, which offer familiarity with language and culture.”

If there is no short-term solution to Ireland’s financial vulnerabilities, a few longer-term needs stand out. Dublin should ensure that its current budget surplus is invested wisely to help diversify its drivers of growth. One such driver would be significant increases in public investment in housing and public transport infrastructure to bring the country closer to Western European standards. Ireland’s tax base should be widened to allow for a wider distribution of income sources. For example, In 2021, Ireland gained just 5 percent of its tax receipts from property taxes, compared to more than 11 percent in both Britain and the United States.

Most importantly, Ireland must deepen its trading relationships outside the English-speaking world. Notwithstanding the country’s 50-year membership of the EU, a dearth of foreign language teaching has created a monolingual business culture, which priorities existing links with the United States over the development of new markets, both within and outside the EU. This needs to change if Ireland is to build a sustainable economic model.

Biden—whose family, like so many in the United States, has Irish roots—said in 2021 that “everything between Ireland and the United States runs deep.” This is Ireland’s economic reality today. As the corporate tax boom ebbs, Ireland should ensure that its American dream doesn’t become a recurring economic and financial nightmare.

2 notes · View notes

global-research-report · 17 hours ago

Text

Packaging Machinery Market Size, Share, & Forecast 2025 to 2030

The global packaging machinery market size is expected to reach USD 80.96 billion by 2030, registering to grow at a CAGR of 5.5% from 2025 to 2030 according to a new report by Grand View Research, Inc. A significant increase in the demand for convenience food products is driving industry growth. Convenience food includes all types of packaged food products. The demand for packaged food is mainly contributed by the millennial and gen-z customers who are more inclined towards ease and convenience. The industry growth is also attributed to the rising need for differentiation in retail shops since customers are demanding greater product diversity and a wider range of products.

Packaging differentiation calls for the attention of the customer by using unique sizes, shapes, and materials. This subsequently leads to an increasing inclination of manufacturers toward unique packaging styles and drives product growth. Packaging equipment is used in the pharmaceutical industry for packaging medicines and drugs in a safe environment. The pharma industry has witnessed significant growth over the last decade owing to the increased demand for pharmaceutical drugs in BRICS and MIST countries. The development of new generic drugs and medicines has also fueled the pharma industry's growth. The growing e-commerce industry across the world, rising internet penetration & number of e-commerce players, changing lifestyles, and developments in logistics are facilitating the growth of e-commerce shopping.

Gather more insights about the market drivers, restrains and growth of the Packaging Machinery Market

Packaging equipment is required throughout the e-commerce supply chain stages. Therefore, a rise in the e-commerce industry is expected to propel the packaging equipment industry growth over the forecast period. The market experienced a setback during the COVID-19 pandemic. As a result of supply chain disruption and lack of workforce availability, product demand was impacted. A high number of COVID-19 cases across the globe affected consumer shopping at retail shops and convenience stores. Key companies are actively focusing on strategies, such as technological developments, joint ventures, mergers, and acquisitions, to strive in the competitive industry. In Feb 2022, SIG Combibloc Group Ltd. acquired packaging company, Scholle IPN. It enables SIG to offer sustainable low-carbon packaging solutions across various product types and sizes.

Browse through Grand View Research's Advanced Interior Materials Industry Research Reports.

The global specialty printing consumables market size was valued at USD 39.70 billion in 2024 and is expected to grow at a CAGR of 3.2% from 2025 to 2030.

The global mining drills and breakers market sizewas estimated at USD 17,492.9 million in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030.

Packaging Machinery Market Segmentation

Grand View Research has segmented the global packaging machinery market based on machine type, application, and region:

Packaging Machinery Machine Type Outlook (Revenue, USD Billion, 2018 - 2030)

Filling

Labelling

Form Fill & Seal

Cartoning

Wrapping

Palletizing

Bottling Line

Others

Packaging Machinery Application Outlook (Revenue, USD Billion, 2018 - 2030)

Beverages

Food

Chemicals

Personal Care

Pharmaceuticals

Others

Packaging Machinery Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

Canada

Mexico

Europe

Germany

Russia

Spain

Italy

Asia Pacific

China

India

Japan

Australia

South Korea

Central & South America

Brazil

Middle East & Africa

Saudi Arabia

UAE

Key Companies profiled:

Langley Holding plc

Maillis Group

Rovema GmbH

Douglas Machine Inc.

KHS Group

SIG

Tetra Laval International S.A.

Krones AG

M.A. Industria Macchine Automatiche S.p.A.

Syntegon Technology GmbH

ProMach

GEA Group Aktiengesellschaf

Sacmi

Coesia S.p.A.

Duravant

Key Packaging Machinery Company Insights

Some of the key players operating in the packaging machinery market include Tetra Laval International S.A., Krones AG, I.M.A. Industria Macchine Automatiche S.p.A, Sacmi, and GEA Group Aktiengesellschaft.

Tetra Laval International S.A. was established in 1993 and is headquartered in Pully, Switzerland. It is a leading multinational company that provides a wide range of systems for the processing, packaging, and distribution of food. The company consists of three industry groups, namely Tetra Pak, Delaval, and Sidel. Tetra Pak manufactures processing, packaging, and distribution machinery for liquid and food products including liquids, ice creams, processed foods, fruits, and vegetables. The company’s production facilities supply packaging material to more than 8,800 packaging machines across the globe. Sidel manufactures plastic packaging and complete packaging lines. Delaval is engaged in the manufacturing of equipment and complete systems for animal husbandry and milk production.

Krones AG was established in 1951 and is headquartered in Neutraubling, Germany. The company is engaged in the manufacturing of processing, filling, and packaging lines as well as individual machinery for filling beverages in cans or glass and plastic bottles. It caters to a large set of customers including breweries; juice & soft drink manufacturers; producers of spirits, wine, & sparkling wine; and companies in the liquid food industry. The company also caters to chemical, pharmaceutical, and cosmetic industries. It also offers innovative digitization and intralogistics solutions to its customers. The company’s business segments include digitalization, process technology, bottling & packaging equipment, intralogistics, and lifecycle service. The company’s bottling and packaging equipment segment consists of labeling technology, inspection technology, cleaning technology, plastics technology, packaging filling technology, palletizing technology, and conveyer technology.

Recent Developments

In February 2024, IMA Group, a producer of automatic machines for pharmaceutical, food, and battery processing and packaging, unveiled two artificial intelligence (AI) solutions designed to improve the efficiency and effectiveness of its customer services. The IMA Sandbox solution is a collaborative, cloud-based platform that facilitates co-development and partnership in creating advanced algorithms within a secure and shared environment.

In July 2024, Eliter Packaging Machinery launched its newest model of automatic sleeving machine, the Multi-Wrap C-80S, designed for multipacks with a maximum speed of 80 wraps per minute. This machine efficiently groups packaging containers such as cans, bottles, cups, and pots into various configurations, ranging from 1x2x1 to 1x4x1, as well as cluster-pack formats like 2x2x1 and 2x3x1. It features a grouping system that enables quick changeovers to accommodate different packaging arrangements.

In July 2024, Cama Group introduced a new top-loading packaging machine, the MTL. This flexible, modular system significantly enhances the efficiency of packaging a variety of boxes.

Order a free sample PDF of the Packaging Machinery Market Intelligence Study, published by Grand View Research.

#Packaging Machinery Market

0 notes

trendsofmarket · 4 days ago

Text

Analysis of Pharmaceutical Contract Manufacturing and Research Services Market Outlook and Forecasts by Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysis

Research Nester assesses the growth and market size of the global pharmaceutical contract manufacturing and research services market which is anticipated to account for the rising generics demand, increased pharmaceutical R&D spending, and contract manufacturing and research services investments in sophisticated manufacturing technologies.

Request Report Sample@

Research Nester’s recent market research analysis on “Pharmaceutical Contract Manufacturing and Research Services Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor analysis and an overview of the global pharmaceutical contract manufacturing and research servicesmarket in terms of market segmentation by service, end user and by region.

Growing Demand for Biological Therapies to Promote Global Market Share of Pharmaceutical Contract Manufacturing and Research Services

The pharmaceutical contract manufacturing and research services business is expanding due to the expiring patents of certain drugs. While the branded pharmaceutical sector has suffered huge revenue and volume losses due to patent expiration, numerous new, less expensive generic alternatives are now entering the pharmaceutical contract manufacturing and research services marketplaces. A promising indication for the expansion of the pharmaceutical contract manufacturing and research services market over the projection period is the fact that generic companies are outsourcing their production to these services.

Access our detailed report at:

Some of the major growth factors and challenges that are associated with the global pharmaceutical contract manufacturing and research servicesmarket are:

Growth Drivers:

SMEs' Budgetary Restrictions

Commercial Success of Biologicals For Clinical Applications

Challenges:

The primary hindrance to the growth of this market is the presence of sizable pharmaceutical corporations with in-house medication manufacturing capabilities. These companies develop their candidate drugs, conduct internal studies, and conduct clinical trials. Many companies are steadily inclined to boost their manufacturing capacity and no longer rely on outsourced services to meet the global demand for pharmaceuticals.

By service, the global pharmaceutical contract manufacturing and research servicesmarket is segmented into manufacturing and research. The manufacturing segment is to register a significant CAGR during the forecast period. The increasing demand for vaccines and biosimilars is one of the main drivers of the segment's growth. The increase in companies opting to outsource the manufacturing of pharmaceutical finished goods, clinical trial materials, and active pharmaceutical ingredients (APIs) explains the profitable growth rate.

By region, the Europe pharmaceutical contract manufacturing and research services market is expected to register rapid revenue CAGR by the end of 2037. Increased funding for pharmaceutical R&D, strong intellectual property laws, shifting demographics, and a higher danger of epidemics are a few of the causes of this expansion. Furthermore, according to the European Commission, half of the pharmaceutical imports into the world's fastest-growing markets come from Europe.

This report also provides the existing competitive scenario of some of the key players of the global pharmaceutical contract manufacturing and research services market which includes company profiling of AbbVie, Recipharm AB, Baxter BioPharma, Dalton Pharma Services, Thermo Fisher Scientific Inc., Piramal Pharma Solutions, Jubilant Pharmova Limited, Samsung Biologics and others.

Request for customization @

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

#pharmaceutical-contract-manufacturing-and-research-services-market-trends #pharmaceutical-contract-manufacturing-and-research-services-market-share

0 notes

industrynewsupdates · 5 days ago

Text

Pharmaceutical Packaging Market Trends, Opportunities, and Challenges 2024 - 2030

The global pharmaceutical packaging market was valued at USD 139.37 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030. A key driver of this growth is the substantial expansion of the pharmaceutical sector itself. In recent years, the pharmaceutical industry has experienced rapid growth, fueled by continuous advancements in science and technology. This upward trend is expected to persist throughout the forecast period, especially in developing countries such as China, India, Saudi Arabia, and Brazil, where the healthcare infrastructure and pharmaceutical demand are expanding quickly.

The United States is the largest pharmaceutical market in the world. Several factors contribute to this dominance, including the size of the healthcare system, high per capita income, and substantial investments in drug development within the country. These elements collectively drive the growth of the pharmaceutical sector in the U.S. Additionally, the increasing importance of generic drugs and broader access to better healthcare services are expected to create further growth opportunities for pharmaceutical packaging in the coming years.

A significant piece of legislation, the 21st Century Cures Act, was signed into law in the U.S. on December 13, 2016. This act is designed to expedite the development of medical products, including pharmaceutical drugs, by enhancing the approval process and encouraging innovation in the industry. The implementation of the Cures Act is expected to spur new developments in pharmaceutical products, which will, in turn, drive the demand for pharmaceutical packaging in the U.S. market. These factors collectively indicate a continued growth trajectory for the pharmaceutical packaging industry, especially in key markets such as the U.S.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

Regional Insights

North America

North America dominated the pharmaceutical packaging market with a revenue share of 35.9% in 2023. The largest end-use segment in the region was pharma manufacturing, which includes in-house production of pharmaceutical products. The presence of a substantial number of pharmaceutical plastic bottle manufacturers in the U.S., such as AptarGroup Inc., Gerresheimer AG, Amcor Ltd., and Berry Plastics Group, Inc., is expected to have a positive impact on the demand for pharmaceutical plastic bottles over the forecast period. These companies play a critical role in supplying the packaging materials required for pharmaceutical products, further driving market growth.

Asia Pacific

The Asia Pacific region is anticipated to register the fastest CAGR of over 12% from 2024 to 2030. This growth is driven by increasing health awareness among consumers, particularly in developing countries such as China and India, and rising disposable income levels. As a result, the demand for pharmaceuticals is expected to grow, which will in turn boost the need for pharmaceutical packaging solutions. In 2020, China led the Asia Pacific market and is expected to maintain this position due to government initiatives like Healthy China 2020, as well as a growing aging population and expanding contract-manufacturing activities. These factors contribute to the increasing demand for pharmaceutical packaging in the region.

Europe

In Europe, the pharmaceutical packaging market is expected to experience significant growth due to rising research and development (R&D) activities and the continuous introduction of new medicines aimed at improving patient health and quality of life. Companies such as BioNTech SE and CureVac in Europe have made notable achievements, particularly with their successful vaccine development in 2020. These successes have attracted further investments into the biotech industry in countries like Germany, Russia, and the U.K., propelling the growth of pharmaceutical packaging in the region.

The Saudi Arabian pharmaceutical packaging market is one of the major players in the Middle East & Africa region. International pharmaceutical companies are recognizing the potential of the Middle Eastern and North African (MENA) market. For example, Sanofi is a leading player in Morocco, and GlaxoSmithKline leads the market in Saudi Arabia. In addition, local pharmaceutical companies such as SPIMACO and Hikma from Jordan and Saudi Arabia are aiming to become regional leaders. These developments are expected to drive the demand for various pharmaceutical packaging materials in the region during the forecast period.

Browse through Grand View Research's Plastics, Polymers & Resins Industry Research Reports.

• The global flexible paper packaging market size was estimated at USD 50.35 billion in 2023 and is projected to grow at a CAGR of 4.2% from 2024 to 2030.

• The global seaweed packaging market size was valued at USD 699.23 million in 2023 and is expected to expand at a CAGR of 6.6% from 2024 to 2030.

Key Companies & Market Share Insights

The global pharmaceutical packaging market is highly competitive, with numerous players competing for market share. To strengthen their positions, key players are increasingly focusing on acquisitions, which is intensifying the competition within the market. These companies directly compete with each other to secure contracts from large pharmaceutical manufacturers. As a result, the level of competitive rivalry in the market is high.

To differentiate themselves in this competitive landscape, companies are focusing on offering value-added services to attract more clients. Common processes employed by packaging manufacturers to enhance their offerings include spray painting, ultraviolet (UV) coating, and metallization to color packaging containers. Additionally, packaging companies are incorporating various anti-counterfeit measures, such as barcodes, holograms, sealing tapes, and radio frequency identification (RFID) technologies to ensure product authenticity and security.

Notable developments in the market include:

• In November 2023, Amcor Plc, a leading global provider of packaging solutions, announced a Memorandum of Understanding (MOU) with NOVA Chemicals Corporate, a producer of sustainable polyethylene. Under the agreement, Amcor will procure mechanically recycled polyethylene resin (rPE) from NOVA Chemicals for use in the production of flexible packaging films. This partnership supports Amcor’s commitment to sustainable packaging by increasing the use of recycled materials, contributing to the circularity of packaging.

• In July 2023, Constantia Flexibles introduced a new pharmaceutical packaging solution called REGULA CIRC, which uses coldform foil. The packaging replaces conventional PVC with a PE sealing layer, resulting in reduced plastic content and a higher proportion of aluminum. This shift not only enhances the sustainability of the packaging but also improves material recovery during the recycling process.

• In April 2023, Südpack launched its PharmaGuard blister, a new polypropylene-based blister packaging. This product is designed to offer an exceptional water vapor barrier and effective resistance to UV light and oxygen, making it suitable for the packaging of sensitive pharmaceutical products that require enhanced protection.

Key Pharmaceutical Packaging Companies:

• Amcor plc

• Becton, Dickinson, and Company

• AptarGroup, Inc.

• Drug Plastics Group

• Gerresheimer AG

• Schott AG

• Owens Illinois, Inc.

• West Pharmaceutical Services, Inc.

• Berry Global, Inc.

• WestRock Company

• SGD Pharma

• International Paper

• Comar, LLC

• CCL Industries, Inc.

• Vetter Pharma International

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.

#Pharmaceutical Packaging Market #Pharmaceutical Packaging Market size #Pharmaceutical Packaging Market share #Pharmaceutical Packaging Market analysis #Pharmaceutical Packaging Industry

0 notes

marketsndata · 5 days ago

Text

Global Gastrointestinal Drugs Market Size, Share, Growth and Forecast 2031

Global gastrointestinal drugs market is projected to witness a CAGR of 4.23% during the forecast period 2024-2031, growing from USD 45.20 billion in 2023 to USD 62.96 billion in 2031. The market’s growth is boosted by the rising cases of gastrointestinal diseases, novel product launches by the market players, and increasing emphasis on ensuring the availability of gastrointestinal drugs in different regions across the globe.

Technological advancements in drug delivery mechanisms and formulations are enhancing the efficacy of gastrointestinal drugs. The advancements include the development of extended-release and delayed-release formulations that aid in improving the bioavailability and absorption of the drugs, resulting in improved patient outcomes. Such developments are revolutionizing the treatment of ulcerative colitis and Crohn’s disease, among others, providing lucrative growth opportunities for the market.

The rising prevalence of various gastrointestinal disorders, such as celiac disease, is also propelling the growth of the global gastrointestinal drugs market. According to an article published in the StatPearls journal of StatPearls Publishing LLC in August 2023, the prevalence of celiac disease is approximately 0.5% to 1% among the general population. Additionally, the number of cases of Crohn’s disease is also increasing at a rapid rate. According to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, more than half a million people are suffering from Crohn’s disease in the United States. Thus, various pharmaceutical companies are investing in research activities to augment the development of novel therapies to combat the growing threat of Crohn’s disease. In October 2023, Eli Lilly and Company announced that the investigational interleukin-23p19 antagonist, mirikizumab met all major secondary and co-primary endpoints in a phase 3 study, evaluating its efficacy and safety for treating adults with severely to moderately active Crohn’s disease.

Increasing Cases of Gastrointestinal Diseases Boost Market Demand

The rising cases of gastrointestinal distress in various regions across the globe due to changes in lifestyle and eating habits of the population is one of the major factors bolstering the global gastrointestinal drugs market demand. Factors such as increased stress and the rising prevalence of obesity are also propelling the incidences of gastrointestinal diseases. According to the estimates of the World Health Organization (WHO), 1 in 8 people around the world were living with obesity in 2022. This increase is augmenting the incidences of diseases such as peptic ulcers, irritable bowel syndrome, and gastroesophageal reflux disease. Furthermore, the rapid expansion of the aging population is also boosting the demand for gastrointestinal drugs as the older population is more susceptible to gastrointestinal issues. The WHO estimates that approximately 1 in 6 people across the globe will be 60 or older by 2030. Due to the rising occurrences of such issues, pharmaceutical companies are also increasingly focusing on developing innovative therapies that address the underlying cause of the disease rather than alleviating symptoms.

Rising Efforts of Pharma Companies Supports Market Expansion

The rising efforts of the key players in the market to ensure the availability of novel gastrointestinal drugs through investments and partnerships is boosting the global gastrointestinal drugs market size. In June 2024, AbbVie Inc. secured its position in the gastrointestinal drugs market by paying USD 150 million to China-based FutureGen Biopharmaceutical (Beijing) Co., Ltd. in near-term fees for rights to antibody drug targeting TL1A molecule that has been linked with a heightened immune response in cases of inflammatory bowel disease.

Similarly, in June 2024, Akum Drugs and Pharmaceuticals Ltd. unveiled new formulations for gastrointestinal diseases for patients in India. The company’s Rabeprazole + Levosulpiride SR Capsules received approval from the Drug Controller General of India (DCGI). The drugs aim to provide relief to patients suffering from gastrointestinal tract disorders. Rabeprazole sodium, a potent antisecretory compound, has demonstrated efficacy in treating duodenal and gastric ulcers along with gastroesophageal reflux disease by selectively inhibiting the secretion of gastric acid. Such efforts are expected to aid patients suffering from gastrointestinal issues in effectively managing their conditions and provide lucrative growth opportunities to the gastrointestinal drug market.

Retail Pharmacies Hold Significant Market Share

The segment’s expansion can be attributed to the rising requirement for over-the-counter (OTC) gastrointestinal drugs over the past few years due to the rising cases of gastrointestinal distress and consumer preference for immediate relief from common digestive issues, including constipation, acid reflux, diarrhea, and heartburn. As per the American College of Gastroenterology (ACG) estimates, approximately 20% of the population of the United States suffers from gastroesophageal reflux disease. Due to the widespread presence of retail pharmacies and their convenient nature, patients suffering from gastrointestinal issues prefer them for purchasing medication, especially in semi-urban and urban locations.

Meanwhile, online pharmacies are expected to grow rapidly over the next few years due to the growing preference for online shopping, fast delivery, shipping, and the availability of lucrative discounts. Other advantages online pharmacies offer include increased consumer accessibility to a broad range of products. Additionally, the growing popularity of digital consultation and the rising availability of e-prescriptions have also made it easier for patients to avail themselves of the required medications through online pharmacies, bolstering the segment’s growth.

North America Holds Major Market Share

The growth of the North American gastrointestinal drugs market can be attributed to the increasing efforts of the leading market players based in the region to ensure novel product launches, rising cases of gastrointestinal diseases, and the presence of well-established healthcare and pharmaceutical sectors. Various gastrointestinal diseases, including ulcerative colitis, Crohn’s disease, and inflammatory bowel disease, are becoming increasingly prevalent in the United States, bolstering the market’s demand. As per the estimates of the US Centers for Disease Control and Prevention, the prevalence of inflammatory bowel disease is between 2.4 and 3.1 million in the United States, with differing burdens across groups. Additionally, the prominent presence of various research organizations that are increasingly focusing on investigating different gastrointestinal diseases is also expected to influence the market’s expansion positively. Moreover, the increasing availability of novel drugs due to the increasing provision of approvals by the regulatory bodies in the region is also supporting the market’s growth is the region. In 2023, the US Food and Drug Administration (FDA) provided approval to five new gastrointestinal targeted drugs, including colonoscopy prep, inflammatory bowel disease, and gastroesophageal reflux disease. Such approvals are expected to increase the influx of various gastrointestinal drugs in North America.

Download Free Sample Report

Future Market Scenario (2024-2031F)

As per the global gastrointestinal drugs market analysis, the market is expected to witness significant growth in the coming years due to the growing burden of different gastrointestinal diseases and the increasing efforts of the market players towards novel product launches. According to an article published in January 2024 in the Dovepress of the Dove Medical Press Ltd, the prevalence of Crohn’s disease is expected to increase to 1% in 2030 in Western European countries and the United States. This increase will bolster the market’s demand to meet the growing drug requirement for effective management and treatment of the condition. The cases of gastrointestinal distress are also expected to increase in the coming years due to the increasing preference for fast foods and dining out as a fast food-filled diet lacks essential fiber intake, resulting in decreased adoption of water.

Additionally, the market is also expected to witness significant growth over the forecast period due to the rising investments by the leading pharmaceutical companies towards research and development activities and the emphasis on creating targeted therapies that provide minimal side effects along with long-term relief. Furthermore, the growing efforts of various countries to enhance their healthcare sectors and ensure the availability of necessary therapies and treatment solutions are further expected to propel the global gastrointestinal drugs market growth.

Report Scope

“Gastrointestinal Drugs Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gastrointestinal drugs market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/gastrointestinal-drugs-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: [email protected] Website: https://www.marketsandata.com

#Gastrointestinal Drugs Market #Global Market #Market Research Reports #Market News

0 notes

voizmed · 14 days ago

Text

Advantages of Solan Pharma Third-Party Manufacturing

With the growing demand for pharmaceuticals, the third-party manufacturing model has emerged as a game-changer for companies seeking efficient, cost-effective production solutions.

Solan, a picturesque town in Himachal Pradesh, India, has positioned itself as a prominent hub for third party pharma manufacturing. Known for its world-class facilities, skilled workforce, and regulatory compliance, Solan offers a unique ecosystem that has drawn companies from across the country.

Let’s explore the advantages of choosing Solan for third-party pharma manufacturing:

1. Access to WHO-GMP Certified Facilities

One of the major advantages of opting for Solan as a third-party manufacturing destination is the access to WHO-GMP (Good Manufacturing Practice) certified facilities.

Pharmaceutical companies can rest assured that Solan-based manufacturers follow international standards in production, ensuring the highest quality and safety of pharmaceutical products.

2. Cost Efficiency and Resource Savings

Setting up an in-house manufacturing unit can be a heavy financial burden, especially for small and medium-sized companies. Solan’s third-party manufacturing services offer a cost-effective solution, allowing companies to save significantly on infrastructure, machinery, and labor costs.

By outsourcing manufacturing, pharma companies can allocate more resources toward R&D, marketing, and distribution, maximizing their budget in a highly competitive market.

3. Skilled and Experienced Workforce

Solan is home to a highly skilled workforce specializing in pharmaceutical manufacturing.

With trained technicians, quality control experts, and R&D professionals, the region boasts a talent pool that has been instrumental in maintaining the high standards that Solan-based manufacturers are known for.

4. Proximity to Raw Material Suppliers

Solan’s geographic location in Himachal Pradesh, close to several raw material suppliers and allied industries, is a logistical advantage. The easy availability of high-quality raw materials reduces delays and transportation costs, enabling manufacturers to deliver on time while keeping production costs low.

5. Regulatory Compliance and Quality Assurance

Solan’s third-party manufacturers are known for their strict adherence to regulatory requirements. They comply with DCGI (Drug Controller General of India) and other regulatory body guidelines, which guarantee the quality and efficacy of the products they produce.

6. Flexibility and Scalability in Production

One of the unique advantages of 3rd party pharma manufacturing in Solan is the flexibility it offers. Pharma companies can scale up or down their production volumes based on market demand, without the long-term commitments required for in-house production.

7. Focus on Innovation and New Product Development

With manufacturing in the hands of a reliable third-party provider, companies can focus more on innovation and new product development. Solan’s manufacturing ecosystem supports a range of pharmaceutical formulations, from tablets and capsules to specialized syrups and injectables, allowing pharma companies to expand their product portfolios with ease.

Conclusion

For pharmaceutical companies seeking a trusted, efficient, and scalable manufacturing solution, Solan’s third-party pharma manufacturing services offer a compelling array of advantages.

From cost savings and high-quality standards to scalability and market expansion, Solan’s manufacturers provide a strategic option for businesses aiming to grow while maintaining product quality.

#PharmaceuticalManufacturing #ThirdPartyManufacturing #SolanPharma #PharmaOutsourcing #Solan

0 notes

thirdpartymanufacturers · 14 days ago

Text

Why Third Party Manufacturing is Essential for Pharma Business?

Third Party Manufacturing can be one of the very much strategic decisions of growing and streamlining in the competitive world of pharma. Now, this business model is getting more preference in the past few years, especially for small and medium-sized companies. However, Third Party Manufacturing is vital to the pharma industry. Let's see why.

What is Third Party Manufacturing?

Third Party Manufacturing is the outsourcing of the production of pharma products to a third party manufacturer. A pharma company hires another company to manufacture the products under that third party brand. This can facilitate companies in taking hold of their real strengths, in order to focus on marketing and selling the product as the complexities of the production are left to the experts.

Benefits of 3rd Party Manufacturing

1. Cost Efficiency The most significant advantage of Third Party Manufacturing is cost saving. It calls for a huge amount of investment, such as machinery, labor, and also the regulatory standards, while starting a manufacturing unit. This investment could be completely avoided by the pharma business through the setup of Third Party Pharma Manufacturing Company. Generally, the infrastructure and expertise are already present in the third-party manufacturer. Because of that, the cost of production is heavily reduced.

This could be an important point in the best allocation of resources for companies, such as in R&D, marketing, and distribution. Such goals can be treated as win-win for such companies, since they can be able to have high-quality products with controlled cost.

2. Core Competencies Focus For any pharma business, focus on core competencies is the way forward to realize growth. Innovative product development, an expanded market reach, and connecting with healthcare providers are among key factors playing into a path towards success although often resource-intensive and time-consuming, managing processes for manufacturing.

Outsourcing manufacturing from Third Party Manufacturing Pharma Company frees the company to focus on doing what it does best. The production is outsourced to the partner, and the company can concentrate on other areas such as research, marketing, and sales. With this partnership, pharma companies can stay agile and responsive to market demands without being burdened by the details of production.

3. Speed to Market The pharmaceutical market is fast-paced. New products need to be developed, tested, and launched quickly to remain competitive in the market. Such a requirement needs productive capabilities. Third-party manufacturing reduces the time cycle of getting a product into the market. The contract manufacturing partner already has the facilities, staff, and regulatory know-how for rapid expansion.

By leveraging a 3rd Party Manufacturing partner, companies can promptly respond to market needs and ensure that their products find its way into the consumer's pocket. There's especially no better time than now as it increases demand for other medicines that must be responded to, hence keeping up with the completion level.

4. Expertise and Quality Assurance Third Party Manufacturing companies have vast experience in their bag. They are specialized in manufacturing pharmaceutical products in large quantities with no compromise on quality at all. Familiar with the rules of the industry, GMP, and proper quality control measure. Thus, the produced items will be safe, potent, and compliant with regulatory authorities.

Third Party Manufacturing Companies provide easier access to world-class manufacturing practices for smaller companies or startups, especially those who cannot invest in specialized production facilities that help the company maintain the quality and credibility of its brand.

5. Scalability Flexibility Another major advantage of Third Party Manufacturing is flexibility. Pharma companies can easily up or downscale their production based on demand without the constraints of managing their factory. Manufacturers can ramp up quickly when in high-demand periods and scale down to prevent excess inventory when in low-demand periods.

This scalability will enable businesses to better manage their resources and avoid risks associated with overproduction or stockout. It will help companies improve their adaptability to changing market conditions.

6. Regulatory Compliance and Risk Mitigation The pharmaceutical product line has very high requirements for the products manufactured. Follow all the standards set is very necessary but quite challenging for a business that does not have appropriate infrastructure. In a Third Party Pharma Manufacturing relationship, established procedures exist for meeting regulatory expectations. It also ensures that all items are made following the highest safety and quality considerations.

Also, with a company of good standing in 3rd Party Manufacturing, the risk of compliance violation, product recall, or a lawsuit against fines/penalties against the company dramatically declines. Companies can rely on their partners' knowledge and experience to wade through regulatory complexities.

7. Comprehensive List of Services Third Party Manufacturing companies often provide many services beyond mere manufacturing. Many provide development of formulations, packaging, labeling, and even distribution services. This one-stop-shop approach makes the life of a pharma company easier as it streamlines its whole operation and saves it from dealing with too many different vendors.

Other companies also use Third Party Manufacturing services to offer R&D facilities. Here, companies can share new product lines and innovations without huge investment in R&D. This is a fine way for companies to expand their portfolios overnight.

8. Expansion into New Markets Third Party Manufacturing also allows for the expansion to new markets. For companies that are in a process of seeking entrance into global markets, partnership with an efficient contract manufacturer would hasten the process of achieving local requirements and regulations on production. In most instances, such companies will already have complied with international standards, thereby making it easier to launch products within new regions.

By way of outsourcing manufacturing, pharma companies could focus on developing distributor and retailer partnerships in their new markets, free from the hassles of production logistics, which would help them scale operations globally.

Conclusion In a nutshell, Third Party Manufacturing is a game-changer in the pharmaceutical industry. It provides the benefits in the form of savings on cost, reaching the market quickly, expertise, and above all regulatory compliance. Out-sourcing to a Third Party Manufacturing Pharma Company will enable businesses to focus on core competencies while growing more efficiently.

Whether it is scalability of production, quality of the product, or geographies, 3rd-party manufacturing offers flexibility and resources one needs in the fast game of the pharmaceutical industry. It can unlock growth and success in the ever-evolving market by embracing this model.

#Third Party Manufacturing #Third Party Pharma Manufacturing #Third Party Manufacturing Pharma Company #3rd Party Manufacturing #Third Party Manufacturing Company #Pharma Contract Manufacturing

0 notes

latestmarketresearchnews · 15 days ago

Text

Pharmaceutical Packaging Market 2030 Top Key Players, Trends, Share, Industry Size, Segmentation

The global pharmaceutical packaging market was valued at USD 139.37 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2030. This growth is largely driven by the rapid expansion of the pharmaceutical industry, which has been advancing due to scientific and technological innovations. The ongoing growth is expected to continue, especially in developing regions such as China, India, Saudi Arabia, and Brazil, where healthcare infrastructure and demand for medicines are expanding significantly.

In 2023, the United States represented the largest pharmaceutical market globally. Several factors contribute to this, including a well-established healthcare system, high per capita income, and substantial investments in research and drug development. The increasing focus on generic drugs and the improvement in healthcare services are expected to provide promising opportunities for the pharmaceutical packaging market. Notably, the 21st Century Cures Act (Cures Act), signed in 2016, is aimed at accelerating medical product development in the U.S., thus fostering innovation in the pharmaceutical industry. This legislation is anticipated to boost demand for pharmaceutical packaging by supporting the launch of new and innovative drug formulations.

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

Europe’s pharmaceutical sector is one of its high-performing and technologically advanced industries, significantly contributing to the regional economy. The sector is evolving with an increased focus on developing biopharmaceutical drugs, which has grown over recent years. Many biotechnology-based drug therapies are sensitive to degradation and thus require specialized packaging, such as lyophilized or dry powder forms, to maintain stability. This demand for sophisticated packaging solutions is creating new growth opportunities for packaging manufacturers.

Pharmaceutical products are primarily available in forms such as tablets, capsules, liquids, and powders. They require various packaging solutions, including rigid bottles, stand-up pouches, flat pouches, sachets, and blister packs, each designed to meet specific needs. Packaging companies are now prioritizing features like dispensing aids, administration tools, eco-friendly materials, tamper-evident seals, and anti-counterfeiting measures to enhance product safety, accessibility, and sustainability.

End-use Segmentation Insights:

The pharma manufacturing segment was the largest end-use segment in 2023, accounting for a 49.9% market share, and is anticipated to see strong growth through to 2030. This trend is primarily due to the rising demand for medicines worldwide. According to the World Health Organization (WHO), the global population aged over 60 is expected to nearly double from 12% in 2015 to 22% by 2050, increasing the need for medicines and healthcare. The aging population requires more medical assistance, which is driving pharmaceutical production and, subsequently, the demand for pharmaceutical packaging.

To manage costs and increase efficiency, pharmaceutical companies are increasingly outsourcing packaging activities. By outsourcing, companies can avoid investing directly in packaging materials and equipment, instead working with specialized contractors who provide efficient packaging solutions. This shift is expected to fuel demand for contract manufacturing and pharmaceutical packaging equipment.

Retail pharmacies, especially in developing countries like India, China, and Brazil, are using branding on packaging materials such as polybags and paper pouches to differentiate their products. As retail penetration expands in these regions, the retail pharmacy segment is likely to see significant growth.

Institutional pharmacies, which operate within healthcare facilities like hospitals, nursing homes, and assisted living communities, are expected to grow as well. The increasing number of hospitals and healthcare facilities, along with rising healthcare expenditures, is likely to drive demand for pharmaceutical packaging in this segment. With a growing focus on healthcare accessibility and quality, the institutional pharmacy end-use sector is anticipated to contribute significantly to the overall growth of the pharmaceutical packaging market.

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.

#Pharmaceutical Packaging Market Forecast #Pharmaceutical Packaging Market Overview

0 notes

chemxpert · 14 days ago

Text

Unveiling India’s Pharma Global Market Insights | Chemxpert Database

Chemxpert Database offers an in-depth look into India's booming pharma global market size, highlighting a comprehensive list of pharmaceutical products exported from India. Explore top pharmaceutical export companies in India and understand the Paracetamol manufacturing process with detailed insights into leading paracetamol manufacturers in India. Discover how India’s paracetamol global market practices drive quality and competitiveness, positioning India as a vital player in the global pharmaceutical landscape.

#top chemical raw material manufacturers in India #top pharma raw material manufacturers in India #top listed pharma companies in India #top pharma companies in India by revenue #pharma clinical trial in India #world pharma market size

0 notes

researchreportinsight · 15 days ago

Text

Pharmaceutical Packaging Market 2030 Driving Factors, Future Trends, Size & Key Vendors

Gather more insights about the market drivers, restrains and growth of the Pharmaceutical Packaging Market

End-use Segmentation Insights:

Order a free sample PDF of the Pharmaceutical Packaging Market Intelligence Study, published by Grand View Research.

#Pharmaceutical Packaging Market Forecast #Pharmaceutical Packaging Market Overview

0 notes

trendingrepots · 26 days ago

Text

Adalimumab Market - Forecast(2024 - 2030)

Adalimumab Market Overview

Adalimumab Market Size is forecast to reach $3245.8 Million by 2030, at a CAGR of 6.20% during forecast period 2024-2030. Adalimumab is a monoclonal antibody and disease-modifying antirheumatic medication that acts by inactivating tumor necrosis factor-alpha. It is marketed under the brand names Humira and Exemptia, among others. The original adalimumab drug is sold under the brand name Humira. New versions of adalimumab are known as adalimumab biosimilars. Biosimilars are similar versions of original biological medicines. Adalimumab is a drug used to treat rheumatoid arthritis and ankylosing spondylitis which affects the musculoskeletal system, Crohn’s disease, ulcerative colitis, psoriatic arthritis, hidradenitis suppurativa, and other diseases. It was first introduced in the United States by Abbvie and was approved by the FDA in 2002. It is used to alleviate inflammation by acting on the immune system. The growing prevalence of arthritis and skin disorders, adoption of a sedentary lifestyle, and growing obese population are some of the factors driving the Adalimumab Market growth during the forecast period 2024-2030.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞

Report Coverage

The report: “Adalimumab Market Forecast (2024-2030)", by Industry ARC covers an in-depth analysis of the following segments of the Adalimumab Market.

By Disease- Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis, and others. By Type- Adalimumab, Adalimumab Biosimilar. By End-Users- Hospitals, Specialty Clinics, and Others. By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

Geographically, North America held a dominant market share in the year 2021 on account of the increasing prevalence of psoriasis arthritis, highly informed people knowing the benefits of adalimumab, and high healthcare expenditure. Asia-Pacific is expected to offer lucrative growth opportunities to the manufacturers owing to increasing prevalence of Crohn's disease and ulcerative colitis., demand for better healthcare facilities as well a boost in the investments done by government and private companies in pharma industry. The proliferation of Rheumatoid arthritis is predicted to augment the market growth during the forecast period of 2022-2027.

The growing prevalence of arthritis and skin disorders is estimated to drive the market growth of the Adalimumab Market. High cost as well as lack side effects of adalimumab poses threat to the market growth.

A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Adalimumab Market Report.

#Adalimumab Market price #Adalimumab Market size #Adalimumab Market share

0 notes

mordorintelligencemarketresearch · 1 month ago

Text

India’s Pharma Boom: Trends and Challenges Shaping the Market Landscape

Market Size and Growth

The India Pharmaceutical Market is projected to reach USD 62.93 billion in 2024 and is anticipated to grow to USD 83.90 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.92% during the forecast period from 2024 to 2029.

Market Overview

The Indian pharmaceutical industry is one of the largest in the world, known for its vast generic drug manufacturing capabilities and a robust pipeline of research and development. With a growing demand for affordable healthcare and increasing investment in biotechnology, the sector is poised for substantial growth. The government’s initiatives and favorable policies further bolster the industry's expansion.

Key Trends

Digital Transformation: The integration of digital technologies in manufacturing and supply chain management is streamlining operations and improving efficiency.

Rise of Biologics: There is a noticeable shift towards biologics and biosimilars, driven by advancements in biotechnology and increased patient demand for specialized treatments.

Regulatory Reforms: Recent regulatory changes aimed at expediting drug approvals are enhancing market accessibility and encouraging innovation.

Focus on Sustainability: The industry is increasingly adopting sustainable practices, including green chemistry and waste reduction, to align with global environmental standards.

Telemedicine Growth: The surge in telemedicine usage, especially post-COVID-19, is reshaping pharmaceutical distribution and patient engagement strategies.

Challenges

While the Indian pharmaceutical industry is on a growth trajectory, it faces several challenges, including:

Intellectual Property Concerns: Navigating patent laws and protecting innovations remain significant hurdles.

Quality Control Issues: Ensuring consistent quality across manufacturing facilities is critical, particularly as international scrutiny increases.

Market Competition: Intense competition from both domestic and international players can impact pricing and profitability.

Supply Chain Disruptions: Global supply chain challenges can affect the availability of raw materials and timely delivery of products.

Regulatory Compliance: Keeping up with evolving regulatory requirements can be complex and costly for manufacturers.

Conclusion

The Indian pharmaceutical market stands at a pivotal point of growth, driven by innovation, digital transformation, and increasing healthcare demands. While challenges persist, the opportunities for expansion and diversification are vast. Stakeholders must remain agile and proactive in addressing these challenges to fully capitalize on the promising outlook of this dynamic industry.

#Indian pharmaceutical market #Indian pharmaceutical market size #Indian pharmaceutical market share #Indian pharmaceutical market trends #Indian pharmaceutical market growth #Indian pharmaceutical industry #Indian pharmaceutical industry overview

0 notes

thescience97 · 1 month ago

Text

Leucogen (CAS 1950-36-3) Market Size, Share, and Forecast to 2031

Leucogen Cas 1950 36 3 Market

The latest study released on the Global Leucogen Cas 1950 36 3 Market by Market Strides, Research evaluates market size, trend, and forecast to 2032. The Leucogen Cas 1950 36 3 Market consider covers noteworthy inquire about information and proofs to be a convenient asset record for directors, investigators, industry specialists and other key people to have ready-to-access and self-analysed study to help understand market trends, growth drivers, openings and up and coming challenges and approximately the competitors.

Some of the key players profiled in the study are:

Jibeier Pharma

Ache

Droga Raia

Virbac

Get Free Sample Report PDF @ https://marketstrides.com/request-sample/leucogen-cas-1950-36-3-market

Scope of the Report of Leucogen Cas 1950 36 3 Market :

The report also covers several important factors including strategic developments, government regulations, market analysis, and the profiles of end users and target audiences. Additionally, it examines the distribution network, branding strategies, product portfolios, market share, potential threats and barriers, growth drivers, and the latest industry trends.

Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Affect and Economic Slowdown globally. Keep up a competitive edge by measuring up with accessible commerce opportunity in Leucogen Cas 1950 36 3 Market different portions and developing territory.

The titled segments and sub-section of the market are illuminated below:

By Type

Injection

Oral

By Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Get Detailed@ https://marketstrides.com/report/leucogen-cas-1950-36-3-market

Geographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:

• The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)

• North America (United States, Mexico & Canada)

• South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)

• Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)

• Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).

Objectives of the Report:

•To carefully analyze and forecast the size of the Leucogen Cas 1950 36 3 Market by value and volume.

• To estimate the market shares of major segments of the Leucogen Cas 1950 36 3 Market

• To showcase the development of the Leucogen Cas 1950 36 3 Market in different parts of the world.

• To analyze and study micro-markets in terms of their contributions to the Leucogen Cas 1950 36 3 Market, their prospects, and individual growth trends.

• To offer precise and useful details about factors affecting the growth of the Leucogen Cas 1950 36 3 Market

• To provide a meticulous assessment of crucial business strategies used by leading companies operating in the Leucogen Cas 1950 36 3 Market, which include research and development, collaborations, agreements, partnerships, acquisitions, mergers, new developments, and product launches.

Key questions answered:

• How feasible is Leucogen Cas 1950 36 3 Market for long-term investment?

• What are influencing factors driving the demand for Leucogen Cas 1950 36 3 Market near future?

• What is the impact analysis of various factors in the Global Leucogen Cas 1950 36 3 Market growth?

• What are the recent trends in the regional market and how successful they are?

Buy Leucogen Cas 1950 36 3 Market Research Report @ https://marketstrides.com/buyNow/leucogen-cas-1950-36-3-market

The market research report on the Global Leucogen Cas 1950 36 3 Market has been thoughtfully compiled by examining a range of factors that influence its growth, including environmental, economic, social, technological, and political conditions across different regions. A detailed analysis of data related to revenue, production, and manufacturers provides a comprehensive view of the global landscape of the Leucogen Cas 1950 36 3 Market. This information will be valuable for both established companies and newcomers, helping them assess the investment opportunities in this growing market.

Region Included are: Global, North America, Europe, APAC, South America, Middle East & Africa, LATAM.

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

At long last, Leucogen Cas 1950 36 3 Market is a important source of direction for people and companies.

Thanks for reading this article; you can also get region wise report version like Global, North America, Europe, APAC, South America, Middle East & Africa, LAMEA) and Forecasts, 2024-2032

About Us:

Market Strides, a leading strategic market research firm, makes a difference businesses unquestionably explore their strategic challenges, promoting informed decisions for economical development. We give comprehensive syndicated reports and customized consulting services. Our bits of knowledge a clear understanding of the ever-changing dynamics of the global demand-supply gap across various markets.

Email: [email protected]

#Leucogen Cas 1950 36 3 Market Size #Leucogen Cas 1950 36 3 Market Share #Leucogen Cas 1950 36 3 Market Growth #Leucogen Cas 1950 36 3 Market Trends #Leucogen Cas 1950 36 3 Market Players

0 notes

industrynewsupdates · 2 months ago

Text

Packaging Machinery Market Size and Regional Outlook Analysis, 2030

The global packaging machinery market size is expected to reach USD 66.14 billion by 2030, according to a new report by Grand View Research, Inc, expanding at a CAGR of 4.6% over the forecast period. A significant increase in the demand for convenience food products is driving industry growth. Convenience food includes all types of packaged food products. The demand for packaged food is mainly contributed by the millennial and gen-z customers who are more inclined towards ease and convenience. The industry growth is also attributed to the rising need for differentiation in retail shops since customers are demanding greater product diversity and a wider range of products.

Gather more insights about the market drivers, restrains and growth of the Packaging Machinery Market

Detailed Segmentation:

Machine-type Insights

The form-fill-seal segment is expected to register the fastest growth rate of 5.7% over the forecast period. Horizontal Form Fill Seal (HFFS) machines are packaging techniques for high-production manufacturing structures that serve, pack, and ship edible goods. HFFS saves time and money due to their speed and efficiency, effectively sealing and vacuum sealing products in a shorter time. Rising demand for wrapped foods, such as wrapped vegetables, sandwiches, loaves of bread, etc., in urban areas, is projected to considerably contribute to the growth of the wrapping machine segment. Wrapping machines are also used for industrial and commercial goods. The growing e-commerce industry and increased total production output, especially in emerging industrial economies including China, are expected to drive this segment.

End-use Insights

The food end-use segment dominated the global industry in 2021 and accounted for the maximum share of more than 36.00% of the overall revenue. The growing need for packed food due to convenience and ease is expected to drive the growth of this segment. In addition, there has been a rising consumption of healthy and organic food products, which require a special type of packaging. This is likely to further augmented the demand for packaging equipment. The demand for packaging machines in the beverage industry is likely to be driven by factors, such as the growing consumption of beverages and an increase in the variety of beverage products. Many beverage product companies have expanded their product offerings, thus increasing the demand for highly refined and flexible packaging machines.

Regional Insights

Asia Pacific led the global industry in 2021 and accounted for the maximum share of more than 36.5% of the overall revenue. Rapid population growth and rising consumer purchasing power are likely to fuel the demand for packaged goods, which is anticipated to facilitate regional market growth. Launching production facilities by significant regional players is expected to increase the e-commerce industry, which is anticipated to promote the regional market. North America is primarily driven by the highly established food & beverage industry in the U.S. and Canada. The presence of various multinational food processing and manufacturing companies results in an increased demand for packaging machinery. Technological progress in packaging equipment is also one of the leading factors driving the region’s growth.

Browse through Grand View Research's Food Safety & Processing Industry Research Reports.

• The global beverage cans market size was estimated at USD 41.14 billion in 2023 and is expected to expand at a CAGR of 5.5% from 2024 to 2030.

• The global beverage packaging market size was estimated at USD 157.73 billion in 2023 and is expected to grow at a CAGR of 5.0% from 2024 to 2030.

Key Companies & Market Share Insights

Manufacturers adopt several strategies including acquisitions, mergers, joint ventures, new product developments, and geographical expansions to enhance market penetration and cater to the changing technological requirements of various end-use industries. For instance, in January 2021, ProMach acquired Bartelt (manufacturer of horizontal form fill & seal (HFFS) and fill & seal pouch packaging systems) from KHS Group, the aim of ProMach’s is to boost the portfolio of pouch packaging solutions and enable the company to grow its business by adding a new North American base for flexible packaging solutions.

Some of the prominent players in the global packaging machinery market include:

• Langley Holding plc

• Maillis Group

• Rovema GmbH

• Douglas Machine Inc.

• KHS Group

• SIG

• Tetra Laval International S.A.

• Krones AG

• I.M.A. Industria Macchine Automatiche S.p.A.

• Syntegon Technology GmbH

• ProMach

• GEA Group Aktiengesellschaf

• Sacmi

• Coesia S.p.A.

• Duravant

Packaging Machinery Market Segmentation

Grand View Research has segmented the global packaging machinery market on the basis of machine-type, end-use, and region:

Packaging Machinery Machine-type Outlook (Revenue, USD Billion, 2017 - 2030)

• Filling

• Labeling

• Form-Fill-Seal

• Cartoning

• Wrapping

• Palletizing

• Bottling Line

• Others

Packaging Machinery End-use Outlook (Revenue, USD Billion, 2017 - 2030)

• Beverages

• Food

• Chemicals

• Personal Care

• Pharmaceuticals

• Others

Packaging Machinery Regional Outlook (Revenue, USD Billion, 2017 - 2030)

• North America

o U.S.

o Canada

o Mexico

• Europe

o Germany

o U.K.

o Spain

o Italy

o Russia

• Asia Pacific

o China

o India

o Japan

o Australia

o South Korea

• Central & South America

o Brazil

• Middle East & Africa

o Saudi Arabia

o UAE

Order a free sample PDF of the Packaging Machinery Market Intelligence Study, published by Grand View Research.

#Packaging Machinery Market #Packaging Machinery Market size #Packaging Machinery Market share #Packaging Machinery Market Analysis #Packaging Machinery Industry

0 notes

deshpandeisha · 2 months ago

Text

Advancements in Epilepsy Monitoring Devices: Revolutionizing Seizure Detection

The global epilepsy monitoring devices market size was USD 484.6 Million in 2021 and is expected to register a rapid revenue CAGR of 4.5% during the forecast period. The global epilepsy monitoring devices market is expected to grow at a significant rate in the coming years, owing to the rising prevalence of epilepsy and the increasing demand for non-invasive diagnostic procedures. Epilepsy is a neurological disorder characterized by recurrent seizures that can significantly impact a person's quality of life. According to the World Health Organization (WHO), epilepsy affects approximately 50 million people worldwide, with 80% of these individuals residing in low- and middle-income countries.

The growing incidence of epilepsy is one of the major drivers of the epilepsy monitoring devices market. In addition, the increasing availability of advanced technologies for diagnosis and treatment is also fueling market growth. For instance, the development of wireless technology and the miniaturization of sensors has enabled the production of portable and easy-to-use epilepsy monitoring devices, which are becoming increasingly popular among patients.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1840

Competitive Terrain:

The global Epilepsy Monitoring Devices industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

SK Biopharmaceuticals, UCB S.A., Novartis AG, GSK Plc, Pfizer Inc., Eisai Co, Ltd., Angelini Pharma, Indoco Remedies Ltd, Sun Pharmaceuticals Industries Ltd., and Abbott

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Epilepsy Monitoring Devices market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Epilepsy Monitoring Devices market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Epilepsy Monitoring Devices market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1840

Market Segmentations of the Epilepsy Monitoring Devices Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Epilepsy Monitoring Devices market on the basis of product, application, and region:

Segments Covered in this report are:

Product Portability Outlook (Revenue, USD Million; 2019-2030)

Conventional Devices

Monitoring Devices

Deep Brain Stimulation Devices

Wearable Devices

End-use Outlook (Revenue, USD Million; 2019-2030)

Hospitals

Neurology Centers

Ambulatory Surgery Centers (ASCs) & Clinics

Diagnostics Centers

Others

Regional Outlook (Revenue, USD Million; 2019–2030)

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

UAE

South Africa

Turkey

Rest of Middle East & Africa

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/epilepsy-monitoring-devices-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1840

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report: Ceramic Tiles Market | Life Science Analytics Market

0 notes